مقالات پذیرفته شده در سومین کنگره بین المللی زیست پزشکی
Attempted Biomarkers for Early Detection of Colorectal Cancer
Attempted Biomarkers for Early Detection of Colorectal Cancer
Maryam Vahdani ,1,*Muhammad Sadeqi Nezhad ,2
1. Department of Laboratory Science, Gorgan Branch, Islamic Azad University, Gorgan, Iran 2. Department of Laboratory Science, Young Researchers and Elites Club, Gorgan Branch, Islamic Azad University, Gorgan, Iran
Introduction: Colorectal cancer (CRC) is the leading cause of cancer in both genders death worldwide. CRC has poor prognosis therefore there is an essential need for new diagnostic and prognostic biomarkers to circumvent CRC-related deaths. The crosstalk between gene mutations (i.e., mutations of BRAF, KRAS, and p53 as well as microsatellite instability), and epigenetic alterations (i.e., DNA methylation of CpG island promoter regions) have been proposed to play a central role in tumor growth and survival. The primary goal of this study is to accumulate and analyze all the potential attempted biomarkers and prognostic factors in colorectal cancer patients.
Methods: After conducting a literature review for relevant keywords and related articles through prominent databases like Science Direct, ISI Web of Science, Scopus, and PubMed, the results are as follows.
Results: Biomarkers for CRC diagnosis, prognosis, progression, and treatment are considered to be MSI Resistance, PIK3CA mutations, BRAF mutations, KRAS mutations, APC mutations, Loss of 18qLOH, loss of NDST4, loss of PTEN, TP53 expression, IGFR-1R, and Micro-RNA. Additionally, methylation of DNA in CRC such as, VIM, SEPT9, SFRP2 (Biomarkers for CRC and as DNA-based colon cancer screening tests), and TWIST1, IGFBP3, GAS7, ALX4, SDC2 (Higher methylation levels in CRC compared to normal subjects) are also accounted to be promising diagnostic biomarkers. Furthermore, novel biomarker, circulating monocytes, which expressed early in carcinogenesis is under investigation.
Conclusion: Biomarkers can provide a cost-effective and non-invasive diagnosis for CRC; however, other goals like identification of the best prognostic panel of biomarkers and the characterization of predictive biomarkers to help the selection of the most appropriate therapy, are the key consideration of this strategy.